Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer

Published:2023-09-15 Issue:11 Volume:40 Page:4919-4927
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Shore Neal D.,Mehlhaff Bryan A.,Cookson Michael S.,Saltzstein Daniel R.,Tutrone Ronald,Brown Bruce,Lu Sophia,Fallick Mark,Hanson Sarah,Saad Fred

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02634-7.pdf

Reference16 articles.

1. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97. https://doi.org/10.1093/eurheartj/ehz766.

2. Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109–16. https://doi.org/10.1097/JU.0000000000000714.

3. Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96. https://doi.org/10.1056/NEJMoa2004325.

4. Tisseverasinghe S, Tolba M, Saad F, Gravis G, Bahoric B, Niazi T. Should prostate cancer patients with history of cardiovascular events be preferentially treated with luteinizing hormone-releasing hormone antagonists? J Clin Oncol. 2022. https://doi.org/10.1200/JCO.22.00883.

5. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24. https://doi.org/10.1093/jnci/djm168.